NASDAQ:CYTK
Cytokinetics Stock News
$65.27
-0.0100 (-0.0153%)
At Close: May 08, 2024
Cytokinetics (CYTK) Received its Third Buy in a Row
03:15pm, Tuesday, 14'th Apr 2020
After Morgan Stanley and Needham gave Cytokinetics (NASDAQ: CYTK) a Buy rating last month, the company received another Buy, this
Needham Reiterates a Buy Rating on Cytokinetics (CYTK)
02:59pm, Tuesday, 14'th Apr 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Cytokinetics (CYTK), with a price target of $24.00. The company's shares
Needham Reiterates a Buy Rating on Cytokinetics (CYTK)
02:59pm, Tuesday, 14'th Apr 2020
In a report released today,
Chad Messer
from Needham reiterated a
Buy
rating on Cytokinetics (
CYTK
–
Research Report
), with a price target of
$24.00
. The company’s shares closed last Tuesday at
Cytokinetics suspends enrollment in clinical studies amid COVID-19; shares down 7% premarket
12:17pm, Tuesday, 14'th Apr 2020
Cytokinetics (NASDAQ:CYTK) provides clinical updates in response to COVID-19 pandemic. The company and Amgen have agreed to temporarily suspend enrollment in METEORIC-HF, Phase 1 study of AMG 594 an
Cytokinetics says cash, cash equivalents represent over two years of runway CYTK
11:47am, Tuesday, 14'th Apr 2020
Cytokinetics says cash, cash equivalents represent over two years of runway CYTK
Cytokinetics, Amgen suspend enrollment in Phase 1 study of AMG 594 CYTK;AMGN
11:47am, Tuesday, 14'th Apr 2020
Cytokinetics, Amgen suspend enrollment in Phase 1 study of AMG 594 CYTK AMGN
